
Jazz Pharmaceuticals Guides 2026 Revenue to $4.78B-$4.85B as Ziihera Launch Targets $3B-$5B Peak
Jazz Pharmaceuticals issued 2026 revenue guidance of $4.775B-$4.85B and projected $3B-$5B peak sales for its newly launched cancer drug Ziihera. The update signals confidence in its oncology pivot but carries...























